[Expert Consensus for Image-guided Radiofrequency Ablation of Pulmonary Tumors (2018 Version)].
Bao-Dong Liu,Xin Ye,Wei-Jun Fan,Xiao-Guang Li,Wei-Jian Feng,Qiang Lu,Yu Mao,Zheng-Yu Lin,Lu Li,Yi-Ping Zhuang,Xu-Dong Ni,Jia-Lin Shen,Yi-Li Fu,Jian-Jun Han,Chen-Rui Li,Chen Liu,Wu-Wei Yang,Zhi-Yong Su,Zhi-Yuan Wu,Lei Liu
DOI: https://doi.org/10.1111/1759-7714.12817
2018-01-01
Abstract:Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20–30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80–90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post‐ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.